Introduction
Hairy-cell leukemia (HCL) is a rare lymphoproliferative neoplasm of B cell origin [1] [2] [3] and the tumoral cells correspond to a pre-plasma cell stage of differentiation. 4, 5 They display clonal surface immunoglobulins and express the CD19, CD20, CD22, CD79a, CD25 and CD103 markers, 6 less frequently CD38, CD45RO, CD23, CD15, CD4, CD5 and CD10. 7, 8 Proliferation of the HCL tumoral cells is regulated by growth factors 9, 10 including cytokines and cytokine antagonists and there is a correlation between circulating soluble interleukin-2 receptor (sIL-2R) levels and disease activity. Our group showed previously that the remission achieved by IFN-␣ treatment was correlated with a marked reduction in the serum level of soluble CD23 or sCD23 11 in agreement with the proposed role of CD23 and its soluble cleavage fragment in the proliferation and anti-apoptotic effect in chronic B cell malignancies. 12 The interleukin-1 (IL-1) family of agonists and antagonists is also involved in the regulation of HCL, as evidenced by the modulation of IL-1␤, IL-1 receptor antagonist (IL-1Ra) and IL-1 soluble receptors type I and type II in HCL patients treated with 2-chloro-2Ј-deoxyadenosine (2-CdA). 13 However, there is evidence that tumoral cells accumulation in HCL may result from an imbalance between proliferation and deficient apoptosis. A low rate of p53 mutations was detected in HCL 14 and an elevated level of cyclin D1 mRNA and protein has been observed in HCL but is not due to chromosomal rearrangement. 15 Most cases of HCL show high levels of pRB (product of the retinoblastoma gene), however, pRB expression is not consistently related to cyclin D1 overexpression and the pRB appears to be unmutated and underphosphorylated, therefore should be in its active form. 16 Mannick et al 17 have reported that EBV-transformed lymphoblastoid cell lines and EBV-positive Burkitt cell lines spontaneously display a low level of functional inducible nitric oxide synthase (iNOS) that inhibits apoptosis and Epstein-Barr virus reactivation. Nitric oxide, NO, which has been described as a potent immunoregulator, 18, 19 is synthesised from L-arginine by the enzymes nitric oxide synthases, or NOS.
Recently, we observed that the tumoral cells from B cell chronic lymphocytic leukemia (B-CLL) patients spontaneously expressed a functional iNOS that was increased through CD23 (Fc⑀R2) ligation; here again, the NO released was found to exert an anti-apoptotic role that was reverted by NOS inhibitors and by stimulation of the APO-1/Fas molecule. 21 We decided therefore to investigate whether hairy cells, another chronic B cell leukemia, would display similar features as B-CLL. Our present data indicate that a functional iNOS was detected both in hairy cells from patients and in the ESKOL hairy cell line and that NO also exerted an anti-apoptotic role in these cells.
Materials and methods

Hairy cells
Six patients with characteristic features of HCL were studied. HCL was diagnosed according to standard clinical and laboratory criteria, such as positivity for TRAP (tartrate-resistant acid phosphatase). Samples were obtained from untreated hyperleukocytic (Ͼ10 × 10 9 white cells/l) patients at the time of diagnosis (Laboratoire d'Hématologie, Hô pital Saint Louis, Paris, France) as frozen vials of peripheral blood mononuclear cells (PBMC). After thawing, the cells non-adherent to plastic after 1 h of incubation at 37°C were collected and residual T lymphocytes were removed by rosetting with 2-aminoethyl isothiouronium bromide-treated sheep erythrocytes, followed by a centrifugation at 400 g for 30 min over Ficoll-Paque (Amersham-Pharmacia, Uppsala, Sweden). The nonrosetting leukemic B cells were collected and this population was found to consist of 90-100% B cells, as assessed by immunofluorescence with an anti-CD20 mAb-FITC (Immunotech/ Coulter, Margency, France). Residual monocytes and T lymphocytes never exceeded 10% of the total cell number, with undetectable platelet contamination. The isolated population consisted of у90% hairy cells by standard morphological criteria, as previously described. 11 Alternatively, for two patients, tumoral B cells were positively selected, after removal of plastic adherent cells, by separation using anti-CD19-coated mag-netic beads (Dynal, Oslo, Norway) followed by recovery of the adherent cells with DETACHaBEAD (Dynal), according to the specifications of the manufacturer.
Several HCL lines have been established in vitro, most of them being EBNA positive. Among them, the ESKOL cell line has been extensively characterized and has been widely used as a model for oncogene regulation and late B cell differentiation. 22 This cell line, obtained through the courtesy of Dr C Billard (U400 INSERM, Créteil, France) was routinely maintained in culture in RPMI-1640 medium supplemented with fresh glutamine 2 mM, sodium pyruvate 1 mM, penicillin 100 IU/ml, streptomycin 100 g/ml and with 5% FCS (Myoclone super plus; Gibco, Paisley, UK) in an atmosphere of 5% CO 2 in air. The plasmacytoma cell lines RPMI-8226 and U266, obtained from the ATCC (Rockville, MD, USA) were kept in culture in the same conditions.
Reagents
The general NOS inhibitors N G -monomethyl-L-arginine (L-NMMA) and nitro L-arginine methyl ester (L-NAME) were purchased from Sigma (Saint Quentin Fallavier, France) and the more specific iNOS inhibitor 1400 W [N-(3-(aminomethyl)-benzyl)acetamidine] from Alexis (San Diego, CA, USA). The anti-CD23 monoclonal antibody 135 mAb (IgG 1 isotype) was kindly provided by Dr M Sarfati (Hô pital Notre Dame, Montréal, Canada). 14 C-labelled L-arginine was purchased from NEN (Dreieich, Germany). The strong acid cation exchange resin AG 50W-X8 (100-200 mesh, H form), binding to L-arginine but not to L-citrulline was from Biorad Laboratories (Richmond, CA, USA). All the other reagents were purchased from Sigma.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNAs were prepared from 1-10 × 10 6 cells by a modified single-step guanidinium thiocyanate and phenol/chloroform extraction method, 23 using the Trizol reagent (Gibco) according to the specifications of the manufacturer. Aliquots of 1-2 g were then submitted to RT-PCR as described previously. 21 Briefly, reverse transcription was performed on 2 g of total RNA using the first-strand cDNA synthesis kit (Amersham-Pharmacia) and hexarandom (pdN6) nucleotides as primers. For PCR, following an initial denaturation step of the cDNA at 94°C for 30 s, a step cycle program was set as follows for iNOS and ␤2-microglobulin: denaturation at 94°C for 50 s, annealing at 60°C for 50 s, extension at 72°C for 50 s, for 35 cycles, followed by a final extension at 72°C for 10 min. The same conditions were used for endothelial cNOS PCR, except that 37 cycles were performed. PCR products were run on a 7% acrylamide gel, stained with ethidium bromide, scanned and analysed using the 'NIH Image 1.62b7' software. The following intron spanning oligonucleotides based on the sequences of the corresponding human genes were used: iNOS; forward: 5Ј CGG TGC TGT ATT TCC TTA CGA GGC GAA GAA GG 3Ј and reverse: 5Ј GGT GCT GCT TGT TAG GAG GTC AAG TAA AGG GC 3Ј. The iNOS message is represented by a 259 bp band. ecNOS; forward: 5Ј GCA TCA CCT ATG ACA CCC TCA GCG 3Ј and reverse: 5Ј AGC TCG CTC TCC CTA AGC TGG TAG G 3Ј. The ecNOS message is represented by a 277 bp band. ␤2-microglobulin; forward 5Ј CAT CCA GCG TAC TCC AAA GA 3Ј and reverse: Leukemia 5Ј GAC AAG TCT GAA TGC TCC AC 3Ј. The -microglobulin message is represented by a 165 bp band. The iNOS specific primers (human iNOS amplimer set) were purchased from Clontech (Palo Alto, CA, USA), whereas the ecNOS and ␤2-microglobulin primers were synthesized and purified by Oligo-Express (Paris, France) or Genosys (Cambridge, UK). The human A549 epithelial cell line was used as a positive control of iNOS expression. 24 
Detection of iNOS and ecNOS proteins by FACS analysis
The presence of iNOS and ecNOS was analyzed by flow cytometry on permeabilized cells, using the Cytoperm permeabilization and fixation kit (Serotec, Oxford, UK) or the IS ULTRA Cell Fix-Perm kit (Bioadvance, Emerainville, France), according to the manufacturers' specifications. Briefly, 10 6 treated cells were labelled with 10 l of either an anti-iNOS mAb coupled with FITC (macNOS, clone 6; Transduction Laboratories, Becton Dickinson France) and IgG 2a -FITC as control isotype (Becton Dickinson, Le Pont de Chaix, France). Alternatively, cells were analyzed by indirect fluorescence using a mouse mAb anti-human iNOS (IgG 2b , clone 21C10-D10, kindly provided by Dr R Webber, R&D, Minneapolis, MN, USA) and mouse IgC 2b (Becton Dickinson) as isotypic control, followed by incubation with a goat F(abЈ) 2 fragment antimouse IgG (H+L)-FITC (Immunotech). Cells were then analyzed by flow cytometry on a FACScan using the Lysys 2 and Procyt softwares. The anti-macNOS mAbs are directed against a protein fragment corresponding to the amino acids 961-1144 of murine iNOS and recognize the human enzyme. The anti-human EC-NOS was purchased from Transduction Laboratories. The FITC-labeled anti-CD23 mAb was purchased from Immunotech as the corresponding FITC-labeled mouse IgG 1 isotypic control.
Detection of iNOS by fluorescence microscopy
Purified HCL tumoral cells or ESKOL cells were cytocentrifuged on glass slides and fixed with a cold acetone/ethanol mixture (1 vol/1 vol). The slides were incubated in a humidified chamber, either with a 1/100 dilution of the FITC-conjugated mouse anti-macNOS mAb (clone 6), or with isotypematched IgG 2a mAb (Becton Dickinson) as a control, then stained with 0.1 g/ml Hoechst 33342 dye (Molecular Probe, Eugene, OR, USA) and analyzed using an inverted fluorescence microscope (Leica, Wetzlar, Germany).
Quantification of apoptosis
Cells undergoing early apoptosis were estimated by FACS detection of phosphatidylserine expression at the outer leaflet of the plasma membrane, using FITC-labelled annexin V (Boehringer Mannheim, Mannheim, Germany) and simultaneous labelling with propidium iodide in order to exclude necrotic cells. 25 In some instances, nuclear fragmentation was assessed by fluorescence microscopy using the permeant dye Hoechst 33342 as another marker of apoptosis.
Leukemia
Determination of NOS enzymatic activity in cell homogenates and intact cells
Briefly, 10 7 cells per experimental point were lysed by four cycles of freezing on dry ice and thawing in a Tris 50 mM, HCl buffer pH 7.5, containing the following protease inhibitors: leupeptin 1 g/ml, pepstatin 1 g/ml, bestatin 40 g/ml, chymostatin 10 g/ml, TLCK 50 g/ml (all from Sigma), AEBSF 1 mM (Calbiochem, France Biochem, Meudon, France), and dithiotreitol DTT 5 mM (Sigma). Cell extracts were then centrifuged at 14 000 g for 15 min at 4°C to remove debris. Supernatants (crude homogenates) were collected and tested in triplicate samples for their activity of conversion of 14 C L-arginine into 14 C L-citrulline in the presence of the required co-factors, followed by separation on AG50W X8, as previously described. 21 Alternatively, cells were cultured at 2 × 10 6 /ml in RPMI-1640 medium supplemented with 10% FCS, in the presence or not of 1 mM L-NMMA and 1 Ci/ml of 14 C L-arginine was added in each well for an 18 h culture. Supernatants were collected and the amount of radiolabelled 14 C L-citrulline was quantified as previously described. 21 Statistical analysis was performed with the modified t-test for small samples using the Statview software.
Detection of iNOS protein in HCL and ESKOL extracts by Western blotting
Cytosolic extracts from HCL and ESKOL cells were prepared by submitting the leukemic cells to four cycles of freeze-thawing in a homogenization buffer consisting of Tris 50 mM, EDTA 1 mM, pH 7.4, containing a mixture of proteases inhibitors (leupeptin 10 g/ml, PMSF 100 g/ml, antipain (10 g/ml), pepstatin 10 g/ml, chymotrypsin/trypsin inhibitor 100 g/ml and chymostatin 10 g/ml), and DTT 5 mM. After electrophoresis on an 8% acrylamide gel containing 0.1% SDS, the gel was blotted on to a membrane of nitrocellulose (0.45 M, Schleicher and Schuell, Dassel, Germany) using a wet transfer technique. After destaining, the membrane was incubated overnight at 4°C in a blocking buffer made of Tris 10 mM, NaCl 50 mM, EDTA 2.5 mM pH 7.5, containing 5% non-fat milk, rinsed, then incubated for 2 h at room temperature under agitation with a 1/500 dilution of a specific antiiNOS mAb (macNOS, IgG 1 , clone 54; Transduction Laboratories), directed against the carboxy-terminal portion of the murine macrophage iNOS and cross-reacting with human iNOS, or with the anti-human iNOS mAb 21C10-D10. After washing, the membrane was incubated for 90 min at room temperature with a 1/5000 dilution of a peroxidase-conjugated rabbit anti-mouse IgG (ECL kit; Amersham). Revelation was performed by incubating the membrane, after washing, with the ECL reagent substrate. Detection was visualized by autoradiography after 1 min of contact of the membrane with a Biomax-MR1 film (Kodak, Paris, France). As a positive control for iNOS expression, we used either a lysate of IFN-␥-activated murine macrophage RAW cells, provided with the mAb, or a lysate obtained from A549 cells.
Detection of nitrite
Hairy cells were seeded at 10 6 /ml in RPMI-1640 medium supplemented with 10% FCS in the wells of a 24-well microtitration plate and incubated at 37°C in the presence or not of 1 mM L-NAME or 1 mM nicotinamide. Nicotinamide is an inhibitor of ADP-ribosylation and was previously shown to inhibit the induction of iNOS in murine macrophages. 26 After 48 h of culture, cell-free supernatants were collected and tested for their nitrite content with the Griess reagent, as previously described. 21 
Detection of NO by fluorescence with the DAF-2 DA probe
Cells were loaded for 1 h at 37°C with 10 M of 2-diaminofluorescein diacetate fluorescent probe (DAF-2 DA; Calbiochem). After washing, cells were resuspended in Hank's balanced salt solution at pH 7.4 containing or not 100 M of the specific iNOS inhibitor 1400 W (Alexis), dispensed in the wells of a 24-well titration plate (Nunc, Roskilde, Denmark) and analyzed in a Victor-2 cytofluorometer (LKB-Wallac, EG & G, Evry, France). Fluorescence excitation was 485 nm and the emission was recorded at 535 nm. The plate device was set at 37°C and fluorescence was recorded every 10 min over a 2-h period.
Results
Detection by RT-PCR of inducible NO synthase mRNA in ESKOL and HCL patients B cells
Total RNA was extracted from ESKOL cells during their logarithmic phase of growth, reverse transcribed and amplified in the presence of a couple of amplimers specific for the human iNOS gene. As shown in Figure 1 , a fragment of 259 bp was visualized after electrophoresis, in agreement with the expected size deduced from the sequence of the human iNOS gene. A fragment of similar size was also amplified from RNA of a sub-clone of A549 cells which spontaneously displays iNOS without the need for prior treatment with a mixture of cytokines. In contrast, no PCR-specific product was obtained with RNA from U266 ( Figure 1 ) and RPMI-8226 (not shown) myeloma cell lines, which represent the tumoral counterpart of plasma cells corresponding to the terminal differentiation stage of B lymphocytes. No signal was detected when cDNA was replaced by H 2 O or when Taq polymerase was omitted.
Total RNAs from purified HCL leukemic B cells were also analyzed by RT-PCR and found to be positive for the expression of iNOS mRNA whereas this expression was almost undetectable in normal resting B cells, as shown in Figure 2 . Similar results were obtained when tumoral B cells were purified by negative selection and removal of T lymphocytes by rosetting (Figure 2a) or by positive selection with anti-CD19 magnetic beads (Figure 2b) .
The presence of endothelial constitutive NOS (ecNOS or type 3 NOS) mRNA was not detected in the different HCL tested nor in ESKOL (not shown).
Detection of iNOS protein in ESKOL and HCL patients B cells
ESKOL and cells from HCL patients were tested for the intracytoplasmic expression of iNOS protein by immunofluorescence Leukemia on permeabilized cells followed by flow cytometry analysis. ESKOL cells were positively labelled with a specific antimouse iNOS mAb (anti-macNOS), cross-reacting with human iNOS (Figure 3a) . These results were further confirmed using another anti-iNOS mAb directed against the human protein (Figure 3b ). ESKOL cells were also found to express CD23 (Figure 3c) .
Tumoral B cells from the six HCL patients tested were significantly labelled with the anti-mac NOS, as shown in Figure 4 . Here again, similar results were obtained for negatively selected (HCL NOS 1-4) or positively selected (HCL NOS 5-6) tumoral B cells. About 50-70% of the cells were found to be positive for the expression of iNOS. In contrast, ESKOL and HCL leukemic cells were negative for the expression of ecNOS, as analyzed with an anti-human EC-NOS (not shown).
The presence of the iNOS protein was further assessed by fluorescence microscopy on cytocentrifuged and fixed cells, using the FITC-conjugated anti-macNOS mAb (data not shown). ESKOL displayed a cytoplasmic labelling, as confirmed by simultaneous staining of the nucleus with the Hoechst 33342 dye (data not shown). Tumoral B cells from HCL patients also displayed a cytoplasmic labelling with the anti-iNOS mAb, although fainter (not shown).
Detection by western blotting of the iNOS protein in lysates of ESKOL and hairy cells
As seen in Figure 5 , the presence of iNOS was confirmed by Western blot in lysates of ESKOL cells and tumoral cells from one HCL patient, as well as in the A549 cells (positive control), using the 21C10-D10 anti-human iNOS for the detection. The protein displayed a molecular weight of about 135 kDa, in accordance with the expected value for the human iNOS. In contrast, no iNOS could be evidenced in lysates of the plasmacytoma cell line U266. Similar results were obtained when the anti-macNOS mAb (clone 54) was used (not shown).
Ligation of CD23 on ESKOL stimulates iNOS expression
According to the literature 2,5 and to our previous study, 11 the CD23 antigen is detected on the tumoral cells of about 50% of HCL patients. In agreement with the original description of the ESKOL cell line, 22 CD23 is also highly expressed at the membrane of these cells (Figure 3c ). We reported previously that the engagement of CD23 in B-CLL resulted in an increased iNOS expression and activity. 21 Treatment of ESKOL cells with an anti-CD23 mAb (mAb 135) stimulated the expression of iNOS mRNA, as estimated by semi-quantitative RT-PCR (not shown), and of the corresponding protein, as shown in Figure 6 , using the specific anti-human iNOS mAb 21C10D10 for its detection. Therefore ESKOL cells respond to the cross-linking of CD23 by an increased expression of the iNOS, as it is the case for B-CLL.
NOS activity in HCL and ESKOL extracts
NOS activity was determined in cytosolic extracts of ESKOL cells, either unstimulated or incubated with anti-CD23 mAb or IgG 1 as a control, by measuring the conversion of label- C L-citrulline. These homogenates were found to display a catalytic activity around 20 pmoles/min/mg, that was increased about three times after stimulation with anti-CD23 ( Table 1) . The presence of an enzymatically active NOS in ESKOL cells was further substantiated by the detection of nitrite in their culture supernatants. As seen in Figure 7 , nitrite release was greatly reduced in the presence of L-NMMA, but also of nicotinamide, an inhibitor of ADP-ribosylation, which has been reported to suppress the induction of iNOS in murine macrophages.
For the only case of HCL where the amount of available cells was sufficient to allow its measurement, a significant NOS enzymatic activity was detected that was also increased upon stimulation with anti-CD23 (Figure 8 ). Both basal and CD23-driven NOS activity was markedly reduced in the presence of the NOS inhibitor L-NMMA.
Detection of NO production in ESKOL cells by fluorescence
As seen in Figure 9 , the fluorescence intensity of ESKOL cells loaded with the NO-sensitive probe DAF-2 DA increased linearly with time over a period of 2 h. This increase was significantly reduced in the presence of 1400 W, a specific inhibitor of iNOS. The autofluorescence of ESKOL cells was negligible and the specificity of the probe was checked by the addition of sodium nitroprusside, a chemical NO donor, that markedly stimulated the fluorescence (not shown).
Anti-apoptotic role of NO in leukemic cells of HCL patient
Ligation of CD23 was found to result in a decreased annexin-V labelling, as shown for HCL patient No. 2 in Figure 10 , indicating that the engagement of this molecule resulted in protection towards apoptosis. As we showed previously that this engagement of CD23 led to increased NO expression, the effect of an inhibitor of NO synthase on spontaneous and anti-CD23 driven apoptosis was tested. As seen in Table 2 , addition of L-NMMA resulted in an increased apoptosis of these cells, as measured by the percentage of cells labelled with annexin V. This increase was partially inhibited when cells were treated with anti-CD23. In addition, nuclear fragmentation was quantified in these cells with the Hoechst fluorescent dye. After 3 days of incubation, a marked increase in the percentage of cells displaying characteristic features of nucleus fragmentation was observed for the L-NMMA-treated cells (47%) in comparison with control cells (18%).
Similar data were obtained with ESKOL cells; moreover, after 3 days of culture, incubation of ESKOL with a NOS inhibitor led to significant necrosis (measured with propidium iodide) in addition to apoptosis (not shown). Taken together, these data indicated that NO released through the endogenous iNOS exerted a protective effect towards apoptosis in these cells, that can be abrogated with a NOS inhibitor.
Discussion
NO has been shown to play a role in the control of apoptosis in various cell types, including tumoral cells. The effect of NO on the apoptotic pathway is complex, probably due to the 'double-edged sword' aspect of its action, depending on its concentration and of the redox parameters of the environmental cells where it is released. 27 Our present data indicate that the ESKOL cells, as well as tumoral B cells from patients with HCL, display a functional iNOS. In contrast, no expression of the constitutive type III NOS, which has been reported in some B cell lines and subpopulations of normal B lymphocytes by RT-PCR could be evidenced.
The presence of an iNOS protein in these leukemic cells has been assessed by FACS analysis on permeabilized cells using specific anti-iNOS mAbs and further confirmed by Leukemia Western blotting which allowed the detection in cytoplasmic extracts of a protein of about 135 kDa, in agreement with the molecular weight of the human iNOS. Thus, HCL would appear to behave like B-CLL. In contrast, the results of our observations suggest that iNOS spontaneous expression may be lost in terminally differentiating plasmacytoma, inasmuch as we could not detect its presence in the two myeloma cell lines tested; obviously more experiments on freshly collected myeloma cells are needed in order to ascertain the validity of this observation.
In the case of ESKOL cells and one patient with HCL, NOS activity could be detected in cell lysates by measuring the rate of conversion of L-arginine to L-citrulline inhibited by L-NMMA, indicating that the iNOS protein detected was functionally active. This activity was low, but comparable to that reported previously for B-CLL 21 and for human EBV-transformed B lymphocytes and Burkitt's lymphoma cell lines. 17 The spontaneous release of NO by ESKOL cells was further demonstrated by using the NO-specific fluorescent probe DAF-2 DA which allows the detection in real time of NO in situ. Our results thus confirm and extend those of Eigler et al 28 who reported that ESKOL cells spontaneously synthesize both NO and TNF-␣. TNF-␣ stimulates HCL cell proliferation and the remission achieved with chloro-deoxyadenosine (CdA) is correlated with a serum reduction in circulating TNF-␣ and soluble TNF receptor, sTNR-R60. 29 There is a reciprocal potentiating effect of NO and TNF-␣ on their respective expression, 30 therefore through its stimulating effect on TNF-␣ autocrine secretion, NO could contribute to favor HCL proliferation and escape apoptosis.
In the presence of L-NMMA, the percentage of hairy cells entering apoptosis, as detected by annexin V labelling, is increased whereas it is reduced by engagement of the CD23 molecule. CD23 is expressed on these cells and its engagement leads to increased iNOS expression and activity, as for B-CLL. This would indicate that the NO released plays an antiapoptotic role. The CD23 molecule was reported to play a role in normal B cell proliferation and survival and it has been proposed that in B-CLL the expression of CD23, and notably its a isoform, may be related to cell viability.
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Figure 7
ESKOL cells release nitrite. ESKOL cells were suspended at 5 × 10 5 /ml in complete RPMI-1640 medium and incubated at 37°C for 48 h in triplicate samples in the presence or not of 1 mM L-NMMA or 1 mM nicotinamide. Cell-free supernatants were collected and the amount of nitrite estimated by the colorimetric Griess test. Results are from one experiment representative of three that gave comparable results (*P Ͻ 0.01).
Figure 8
NOS activity in HCL is increased through CD23 ligation. Tumoral cells from HCL patient No. 2 were suspended at 2 × 10 6 /ml in RPMI-1640 + 10% FCS medium. Aliquots of 1 ml each were distributed in triplicate samples in the wells of a 24-well microtitration plate and the cells were stimulated or not with 10 g/ml anti-CD23 mAb 135, in the presence or not of 1 mM L-NMMA. One Ci/ml of 14 C Larginine was added to each cell suspension and to wells containing 1 ml medium alone, without cells. After 18 h of incubation at 37°C, cell-free supernatants were collected and the amount of 14 C L-citrulline formed was estimated after separation on Dowex AG50WX8. Results are expressed as means + s.d. of ⌬ d.p.m., after subtraction of background radioactivity. Statistical analysis between control (medium) and treated cells was performed with 'Statview', using the modified t-test for small samples. *P = 0.05; **P Ͻ 0.01. NS: not significant.
The dual role of NO in apoptosis is now well recognized, [32] [33] [34] [35] although the parameters conferring a pro-or anti-apoptotic role to NO are still poorly understood. As regards the B cell lineage, incubation of ex vivo mature B cells with NO donors was shown to rescue these cells from antigen-induced apoptosis through a cGMP-dependent mechanism and by preventing the drop in the expression of the protooncogene bcl-2, suggesting the existence of a pathway linking NO signalling with Bcl-2 expression. 36 In addition, antipurine drugs evoked a rapid apoptotic cell death in activated B cells and blocked the low but sustained nitric oxide release observed in these cells that contributes to the prevention of apoptotic cell death; the addition of chemical nitric oxide donors significantly antagonized the apoptosis elicited by these drugs.
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Figure 9
Detection in situ of NO production by ESKOL cells with the fluorescent probe DAF-2 DA. ESKOL cells (5 × 10 6 /ml) were resuspended in HBSS and incubated for 1 h at 37°C with 10 M DAF-2 DA. The cells were washed and resuspended at 10 6 /ml in HBSS in the presence or not of 100 M 1400 W. Cells were dispensed at 1 ml/well in a 24-well microtitration plate and fluorescence (excitation: 485 nm; emission: 535 nm) was recorded every 10 min over a 2 h period in a Victor 2 cytofluorometer, set at 37°C. Results are means ± s.d. of quintuplicate samples. /ml in complete medium in the presence or not of 1 mM L-NMMA and together or not with 10 g/ml anti-CD23 mAb 135. After 36 h cells were collected, labelled with annexin V-FITC or goat anti-rabbit Ig F(abЈ) 2 as a control and the percentage of annexin V + cells was estimated by flow cytometry with a FACScan. Results are from one experiment, representative of two. Statistical analysis was performed using the Kolmogorov-Smirnov test. P(1/2) Ͻ 0.001; P(1/3) Ͻ 0.01; P(1/4) Ͻ 0.01; P(2/3) Ͻ 0.001; P(2/4) Ͻ 0.01; P(3/4) Ͻ 0.01.
Noteworthy, Bcl-2 is frequently overexpressed in HCL, although it does not predict a poor response to purine analogues which are largely used in the treatment of this disease. 38 A comparative study of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection has revealed that HIV-unrelated hairy cell leukemia express Bax and Bcl-2 but not Mcl-1. 39 Indeed, NO was shown to suppress apoptosis by inhibiting Bcl-2 cleavage and cytochrome c release from mitochondria. 40 This probably reflects the capacity of NO to inhibit caspase activity which has been reported by several groups and which occurs mainly as a result of S-nitrosylation of the cystein present in the active site of the caspases or oxidation caused by NO. [41] [42] [43] [44] [45] [46] As NO has also been reported to inhibit Fas-mediated apoptosis, 47, 48 this could contribute to the lack of efficiency of the Fas pathway in HCL. Fas expression is moderate in HCL 49 but is increased following culture in vitro. About 50% of the tumoral cells from HCL patients are FAS + but they are resistant to anti-FAS-mediated cytotoxicity, as B-CLL, suggesting that the combination of high bcl-2 protein levels and resistance to anti-FAS-mediated cytotoxicity may contribute to the extended in vivo survival of B-CLL and HCL cells. 50 As stated previously, an impairment of downstream caspase activation has been proposed to explain the inhibition of Fasinduced apoptosis in various tumoral cell types. Moreover, it has recently been reported that engagement of Fas leads to a denitrosylation of the active cysteine, providing a mean of caspase regulation, in addition to the cleavage of the prodomain. 51 Other mechanisms of NO-induced protection towards apoptosis have been described, such as stimulation of NF-B and AP-1 activation 52 or induction of the heat shock protein hsp70. 53 We are currently investigating these different targets in order to better understand the anti-apoptotic effect of NO in chronic B cell malignancies. appreciated. We also thank Jozo Delic for his help in fluorescence microscopy.
